Darwin Global Management, Ltd. - Q3 2021 holdings

$543 Million is the total value of Darwin Global Management, Ltd.'s 12 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 166.7% .

 Value Shares↓ Weighting
XLRN BuyACCELERON PHARMA INC$344,200,000
+55.8%
2,000,000
+13.6%
63.36%
+77.8%
BNTX NewBIONTECH SEsponsored ads$36,289,000132,932
+100.0%
6.68%
FATE BuyFATE THERAPEUTICS INC$20,937,000
-28.2%
353,250
+5.2%
3.85%
-18.1%
INBX BuyINHIBRX INC$18,074,000
+191.3%
542,586
+140.6%
3.33%
+232.4%
NewADAGIO THERAPEUTICS INC$3,655,00086,528
+100.0%
0.67%
VIR NewVIR BIOTECHNOLOGY INC$1,972,00045,311
+100.0%
0.36%
FULC NewFULCRUM THERAPEUTICS INC$959,00033,997
+100.0%
0.18%
AVTE NewAEROVATE THERAPEUTICS INC$262,00012,484
+100.0%
0.05%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-11-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
FATE THERAPEUTICS INC5Q4 202124.2%
KEROS THERAPEUTICS INC5Q1 202312.8%
INHIBRX INC5Q4 20213.9%
ACCELERON PHARMA INC4Q3 202163.4%
AMBRX BIOPHARMA INC4Q3 202367.5%
ARGENX SE4Q3 202370.2%
BRIDGEBIO PHARMA INC4Q3 202125.2%
FULCRUM THERAPEUTICS INC4Q4 20210.9%
ASTRAZENECA PLC3Q2 2022100.0%
INTELLIA THERAPEUTICS INC3Q4 202148.6%

View Darwin Global Management, Ltd.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
42023-06-28
SC 13D/A2023-06-28
SC 13D/A2023-05-25
13F-HR2023-05-15
SC 13G2023-04-03
32023-03-08

View Darwin Global Management, Ltd.'s complete filings history.

Compare quarters

Export Darwin Global Management, Ltd.'s holdings